Wnt / Hedgehog / Notch
StemLight™ Pluripotency Antibody Kit |
イイネ!(0) |
|
| CSTコード | 包装 | 希望納入価格 (円) |
||
|---|---|---|---|---|
| #9656S | 1 Kit | 126,000 | ログインすると国内在庫状況がご確認いただけます。
|
| キット内容 | 容量 | 用途 | 希釈率 | Isotype |
|---|---|---|---|---|
| Oct-4A (C30A3) Rabbit mAb | 100 tests | IF-IC | 1:200 | Rabbit IgG |
| Sox2 (D6D9) XP® Rabbit mAb | 100 tests | IF-IC | 1:200 | Rabbit IgG |
| Nanog Antibody | 100 tests | IF-IC | 1:200 | Rabbit IgG |
| SSEA4 (MC813) Mouse mAb | 100 tests | IF-IC | 1:200 | Mouse IgG3 |
| TRA-1-60(S) (TRA-1-60(S)) Mouse mAb | 100 tests | IF-IC | 1:200 | Mouse IgM |
| TRA-1-81 (TRA-1-81) Mouse mAb | 100 tests | IF-IC | 1:200 | Mouse IgM |
| 貯法 | |
|---|---|
| -20℃ |
| 社内データ |
|---|
IF-IC

Projected confocal z-stack of human iPS cells using TRA-1-60(S) (TRA-1-60(S)) Mouse mAb (green, upper right), TRA-1-81 (TRA-1-81) Mouse mAb (green, upper middle), SSEA4 (MC813) Mouse mAb (green, upper left), Oct-4A (C30A3) Rabbit mAb (green, lower right), Sox2 (D6D9) XP® Rabbit mAb (green, lower middle) and Nanog Antibody (green, lower left). Actin filaments have been labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).
IF-IC

Confocal immunofluorescent analysis of NTERA-2 cells, untreated (left panel) or retinoic acid-treated (10 µM all-trans RA for 5 days) (right panel), using TRA-1-60(S) (TRA-1-60(S)) Mouse mAb (green, upper), TRA-1-81 (TRA-1-81) Mouse mAb (green, middle) and SSEA4 (MC813) Mouse mAb (green, lower). Actin filaments have been labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye). Note the loss of pluripotency markers (green) as cells differentiate along the neuronal lineage with retinoic acid treatment.
IF-IC

Confocal immunofluorescent analysis of NTERA-2 cells, untreated (left panel) or retinoic acid-treated (10 µM all-trans RA for 14 days) (right panel), using Oct-4A (C30A3) Rabbit mAb (green, upper), Sox2 (D6D9) XP® Rabbit mAb (green, middle) and Nanog Antibody (green, lower). Actin filaments have been labeled with DY-554 phalloidin (red). Note the loss of pluripotency markers (green) as cells differentiate along the neuronal lineage with retinoic acid treatment.
IF-IC

Confocal immunofluorescent analysis of NTERA-2 cells, untreated (left panel) or retinoic acid-treated (10 µM all-trans RA for 5 days) (right panel), using Neurofilament-L (C28E10) Rabbit mAb #2837 (green, upper), and β3-Tubulin (TU-20) Mouse mAb #4466 (green, lower). Actin filaments have been labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye). Note the appearance of neuronal markers and structures as cells differentiate along the neuronal lineage with retinoic acid treatment.
| バックグラウンド |
|---|
Pluripotency is the ability of a cell to differentiate into cell types of the three germ layers, the endoderm, ectoderm and mesoderm. It is a property shared by embryonic stem cells, embryonic carcinoma and induced pluripotent cells.Oct-4, Sox2 and Nanog are key transcriptional regulators that are highly expressed in pluripotent cells (1). Together they form a transcriptional network that maintains cells in a pluripotent state (2,3). Over-expression of Oct-4 and Sox2 along with Klf4 and c- Myc can induce pluripotency in both mouse and human somatic cells, highlighting their roles as key regulators of the transcrip- tional network necessary for renewal and pluripotency (4-5). It has also been demonstrated that overexpression of Oct-4, Sox2, Nanog and Lin28 can induce pluripotency in human somatic cells (6). Upon differentiation of pluripotent cultures, expression of Oct-4, Nanog and Sox2 is downregulated.SSEA4, TRA-1-81 and TRA-1-60 antibodies recognize antigens expressed on the cell surface of all pluripotent cells. SSEA4 recognizes a glycolipid carbohydrate epitope (7). TRA-1-60(S) and TRA-1-81 antibodies recognize different proteoglycan epitopes on variants of the same protein, podocalyxin (8). These epitopes are neurominadase sensitive and resistant, respectively. Reactivity of SSEA4, TRA-1-81 and TRA-1-60 antibodies with their respective cell surface markers are lost upon differentiation of pluripotent cells, corresponding with a loss of pluripotent potential (9).
- Looijenga, L.H. et al. (2003) Cancer Res 63, 2244-50.
- Pesce, M. and Schöler, H.R. (2001) Stem Cells 19, 271-8.
- Pan, G. and Thomson, J.A. (2007) Cell Res 17, 42-9.
- Takahashi, K. and Yamanaka, S. (2006) Cell 126, 663-76.
- Okita, K. et al. (2007) Nature 448, 313-7.
- Yu, J. et al. (2007) Science 318, 1917-20.
- Henderson, J.K. et al. (2002) Stem Cells 20, 329-37.
- Draper, J.S. et al. (2002) J Anat 200, 249-58.
- Schopperle, W.M. and DeWolf, W.C. (2007) Stem Cells 25, 723-30.
| 使用例 | |
|---|---|
| 製品をご使用いただいて研究を発表されましたら、ぜひお知らせください。 |
本製品は試験研究用です。
